Clinical Trial Update: Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder [Phase 4]

View source ↗

Summary

A Phase 4 trial update on adjunctive aripiprazole (Abilify) for inadequate response in major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Major Depressive Disorder | Phase 4 | Status: COMPLETED